# Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus

> **NCT00458120** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 36 (actual)

## Conditions studied

- Dengue Hemorrhagic Fever

## Interventions

- **BIOLOGICAL:** rDEN1delta30
- **BIOLOGICAL:** rDEN2/4delta30(ME)
- **BIOLOGICAL:** Placebo to rDEN1delta30 or rDEN2/4delta30(ME)

## Key facts

- **NCT ID:** NCT00458120
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2010-12-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00458120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00458120, "Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00458120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*